Compounded semaglutide doses: what the programs publish
There is no FDA dose schedule for compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy or Ozempic. A dose ladder comes from a label, and no compounded preparation has one. What exists instead is what each program publishes. Of the 14 programs on the chart that publish a compounded semaglutide price, one publishes something about dose, according to GLP Chart's read of their own pages on October 19, 2026.
What each program publishes about dose
| Program | What it publishes about dose | Read on |
|---|---|---|
| Medvi | No dose. Its FAQ prices the first month at $179 and every refill after at $299. | MEDVi FAQ, October 19, 2026 |
| Noom Med | A microdose tier it describes as a fraction of a standard dose, 0.1 mg against 0.25 mg, and calls it off-label. | Noom Med published FAQ, October 19, 2026 |
| Strut Health | No dose. The shot is $149 a month, with auto-refill. | Strut Health pricing, October 19, 2026 |
Units are not milligrams
A compounded vial is filled at whatever concentration the pharmacy chooses, so "20 units" is a volume, not a dose. The same unit count can be a different number of milligrams at two pharmacies, and moving between programs without converting is how people end up taking more or less than they think.
The FDA has published on exactly this. It says it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, from patients measuring and self-administering incorrect doses and in some cases from health care professionals miscalculating them. It also says it has received reports tied to doses beyond what is in the approved label, whether by using more in a single dose, dosing more often, or titrating faster. Read the FDA's statement.
Ask for your dose in milligrams and get it in writing.
What federal rules permit
Compounding is permitted under federal compounding rules in limited circumstances. A compounded product is made by a licensed compounding pharmacy to a prescription; the FDA does not review it for safety, effectiveness or quality, and its formulation, including the salt form, can differ from the approved drug. Confirm the active ingredient and the pharmacy with the prescriber. The FDA's own compounding pages set out what a 503A pharmacy and a 503B outsourcing facility may each do.
If you are pricing this route, two cash programs to check.
No insurance needed.
- SnagRxSponsored$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
- MedviSponsored$299 a monthFirst month $179compounded semaglutideCheck price →Straight to MEDVi's GLP-1 sign-up
Compare every compounded semaglutide program at its maintenance price →
Frequently asked questions
Is there an official dose chart for compounded semaglutide?
No. A dose chart comes from an FDA label and no compounded preparation has one. The pharmacy and the prescriber set the schedule, which is why two programs can put you on different milligrams in the same week.
Why do some programs dose in units instead of milligrams?
Because a compounded vial is filled at a concentration the pharmacy chooses, so units on a syringe only convert to milligrams if you know that concentration. The same unit count can mean different milligrams at two pharmacies. Ask for the milligrams in writing.
Is compounded semaglutide legal?
It is permitted under federal compounding rules in limited circumstances: a state-licensed pharmacy preparing it against a valid prescription. That is a different thing from FDA approval, which no compounded drug has.
Does the dose change what I pay?
On some programs and not others. MEDVi publishes a first-month price and a refill price and names no dose. The chart prices every program at its ongoing maintenance cost so programs are comparable.
This page answers what the programs publish and what the rules permit. It does not tell you which dose to take, and it makes no judgment about whether a compounded product is right for you. That conversation belongs with your prescriber.
Sources
Evidence checked August 31, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. No clinician reviews these pages. What that means.
- Adverse event reports tied to compounded semaglutide dosing errors, to doses beyond the approved label and to faster titration, and the FDA's guidance to prescribers on setting those schedulesFDA's concerns with unapproved GLP-1 drugs used for weight loss
- What 503A and 503B compounding are, and the limited circumstances in which federal rules permit a pharmacy to compoundFDA, human drug compounding